Lefisyo (Levomethadone Hydrochloride)

Levomethadone works by binding to mu‑opioid receptors in the brain and spinal cord, activating them to inhibit the transmission of pain signals. This receptor activation also reduces the emotional response to pain and can alleviate withdrawal symptoms in individuals dependent on opioids.

The appropriate dose of Lefisyo is determined by the prescribing healthcare professional based on the patient’s pain severity, prior opioid exposure, and individual health status. Dosage may be adjusted over time to achieve adequate pain control while minimizing side effects.

Safety data for levomethadone during pregnancy and lactation are limited. Because opioids can cross the placenta and appear in breast milk, the drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To order Lefisyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levomethadone is the levo‑isomer of methadone, offering similar analgesic potency with potentially fewer cardiac side effects at equivalent doses. Compared with morphine or oxycodone, levomethadone has a longer half‑life, which may allow less frequent dosing but requires careful monitoring for accumulation and QT‑interval prolongation.

Lefisyo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure it is out of reach of children and unauthorized personnel.

Lefisyo is administered orally, typically as a tablet or capsule taken with water. The exact route (e.g., with or without food) should follow the prescribing clinician’s instructions to optimize absorption and reduce gastrointestinal side effects.

The most serious risks include respiratory depression, which can be life‑threatening, especially when combined with other CNS depressants; severe hypotension; QT‑interval prolongation leading to cardiac arrhythmias; and the potential for dependence or abuse. Patients should be monitored closely, particularly during dose initiation and adjustments.

Lefisyo should not be used by individuals with known hypersensitivity to levomethadone or any component of the formulation, patients with severe respiratory insufficiency, uncontrolled asthma, or significant obstructive sleep apnea. It is also contraindicated in patients taking monoamine oxidase inhibitors within 14 days of starting therapy.